{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:30:04Z","timestamp":1766212204534,"version":"3.48.0"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: Rasburicase is licensed for the management of tumor lysis syndrome (TLS) at a daily dose of 0.2 mg\/kg intravenously for five days. The use of a single-dose treatment is popular in adult oncology but information in pediatric use is limited. Methods: From a literature search, all case reports and series, and comparative studies in which pediatric oncology patients received a single dose of rasburicase were selected for further analysis. Treatment success was determined by normalization of serum uric acid in the absence of serious complications. Results: Twelve articles with a total of 243 children were included. A fixed-dose regimen was used in 195, while 153 received weight-based dosing. With fixed dosing, successful treatment was seen in 91.8% and 82.9% at rasburicase doses \u22653 mg and 1.5 mg, respectively (p = 0.23). However, there were four mortalities in the lower-dose group. For weight-based dosing, success was observed in 89.2% and 66.7% at doses \u22650.15 mg\/kg and &lt;0.15 mg\/kg, respectively (p = 0.0029). One child required dialysis in the lower-dose group. Conclusions: Single dose of rasburicase for the prophylaxis and treatment of TLS in pediatric oncology is an appealing approach with potentially less financial impact and drug toxicity. A fixed dose of at least 3 mg or 0.15 mg\/kg by body weight is recommended.<\/jats:p>","DOI":"10.3390\/hematolrep17060071","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:42:05Z","timestamp":1766076125000},"page":"71","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-8875","authenticated-orcid":false,"given":"Anselm Chi-wai","family":"Lee","sequence":"first","affiliation":[{"name":"Paediatric Haematology and Oncology Centre, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong, China"},{"name":"Haematology and Oncology Centre, Department of Paediatrics and Adolescent Medicine, Hong Kong Children\u2019s Hospital, 1 Shing Cheong Rd, Kowloon Bay, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lupu\u0219oru, G., Ailinc\u0103i, I., Fr\u0103\u021bil\u0103, G., Ungureanu, O., Andronesi, A., Lupu\u0219oru, M., Banu, M., V\u0103c\u0103roiu, I., Dina, C., and Sinescu, I. (2022). Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051012"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour Lysis Syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12032-023-02108-4","article-title":"Spontaneous Tumor Lysis Syndrome in Patients with Solid Tumors: A Scoping Review of the Literature","volume":"40","author":"Papapanou","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clon.2006.09.005","article-title":"Tumour Lysis Syndrome in Solid Tumours","volume":"18","author":"Gemici","year":"2006","journal-title":"Clin. Oncol."},{"key":"ref_5","first-page":"55","article-title":"Acute Tumor Lysis Syndrome Secondary to a Single-Dose Methylprednisolone in Acute Lymphoblastic Leukemia","volume":"27","author":"Sipahi","year":"2010","journal-title":"Turk. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1034\/j.1600-0609.2001.066006404.x","article-title":"Acute Tumour Lysis Syndrome Following a Single-Dose Corticosteroid in Children with Acute Lymphoblastic Leukaemia","volume":"66","author":"Duzova","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","article-title":"Acute Tumor Lysis Syndrome in Patients with High-Grade Non-Hodgkin\u2019s Lymphoma","volume":"94","author":"Hande","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour Lysis Syndrome: New Therapeutic Strategies and Classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The Tumor Lysis Syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, Clinical Consequences, and Treatment of Tumor Lysis Syndrome","volume":"116","author":"Davidson","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9684909","DOI":"10.1155\/2017\/9684909","article-title":"Tumor Lysis Syndrome in Patients with Hematological Malignancies","volume":"2017","author":"Belay","year":"2017","journal-title":"J. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","article-title":"Urate Oxidase in Prevention and Treatment of Hyperuricemia Associated with Lymphoid Malignancies","volume":"11","author":"Pui","year":"1997","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"433\u2013437; discussion 438\u2013439","DOI":"10.2165\/00128072-200103060-00004","article-title":"Rasburicase","volume":"3","author":"Easton","year":"2001","journal-title":"Paediatr. Drugs"},{"key":"ref_14","unstructured":"FDA (2002). Anon Rasburicase (Elitek) for Hyperuricemia. Med. Lett. Drugs Ther., 44, 96\u201397."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A Randomized Comparison between Rasburicase and Allopurinol in Children with Lymphoma or Leukemia at High Risk for Tumor Lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1345\/aph.1D111","article-title":"Treatment of Impending Tumor Lysis with Single-Dose Rasburicase","volume":"37","author":"Lee","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1592\/phco.26.2.242","article-title":"Reduced-Dose Rasburicase in the Treatment of Adults with Hyperuricemia Associated with Malignancy","volume":"26","author":"Hutcherson","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1592\/phco.28.6.685","article-title":"Evaluation of a Single Fixed Dose of Rasburicase 7.5 Mg for the Treatment of Hyperuricemia in Adults with Cancer","volume":"28","author":"Reeves","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1078155214520821","article-title":"Fixed, Low-Dose Rasburicase for the Treatment or Prevention of Hyperuricemia in Adult Oncology Patients","volume":"21","author":"Herrington","year":"2015","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.leukres.2004.09.004","article-title":"A Single Dose of Rasburicase Is Sufficient for the Treatment of Hyperuricemia in Patients Receiving Chemotherapy","volume":"29","author":"Liu","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1345\/aph.1E002","article-title":"Use of Single-Dose Rasburicase in an Obese Female","volume":"38","author":"Arnold","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1078155210364180","article-title":"Evaluation of a Low, Weight-Based Dose of Rasburicase in Adult Patients for the Treatment or Prophylaxis of Tumor Lysis Syndrome","volume":"17","author":"Knoebel","year":"2011","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jcpt.12479","article-title":"The Optimal Single-Dose Regimen of Rasburicase for Management of Tumour Lysis Syndrome in Children and Adults: A Systematic Review and Meta-Analysis","volume":"42","author":"Yu","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_25","first-page":"130","article-title":"Single Dose of Rasburicase for Treatment of Hyperuricemia in Acute Kidney Injury: A Report of 3 Cases","volume":"5","author":"Hooman","year":"2011","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/0971-4065.139092","article-title":"Single Dose Rasburicase in the Management of Tumor Lysis Syndrome in Childhood Acute Lymphoblastic Leukemia: A Case Series","volume":"25","author":"Latha","year":"2015","journal-title":"Indian. J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.31557\/APJCP.2021.22.12.3897","article-title":"Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience","volume":"22","author":"Appaji","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bjh.14689","article-title":"Single Dose Rasburicase Is a Clinically Effective Pharmacoeconomic Approach for Preventing Tumour Lysis Syndrome in Children with High Tumour Burden","volume":"181","author":"Syrimi","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/08880018.2017.1348415","article-title":"Treatment of Tumor Lysis Syndrome in Children with Leukemia\/Lymphoma in Resource-Limited Settings-Efficacy of a Fixed Low-Dose Rasburicase","volume":"34","author":"Gopakumar","year":"2017","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_30","first-page":"33","article-title":"The Efficacy of Single Dose Rasburicase in Prevention or Treatment of Tumor Lysis Syndrome in Children","volume":"8","author":"Alavi","year":"2016","journal-title":"Iran. J. Blood Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s12098-014-1606-1","article-title":"Low-Dose Rasburicase in Hematologic Malignancies","volume":"82","author":"Jayabose","year":"2015","journal-title":"Indian. J. Pediatr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.clml.2020.08.024","article-title":"Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients","volume":"21","author":"Gupta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/1658-5127.198510","article-title":"Efficacy of Single-Dose Rasburicase in the Management of Tumor Lysis Syndrome: A Case Series from a Regional Cancer Center in Western India","volume":"7","author":"Kukkar","year":"2016","journal-title":"J. Appl. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e27236","DOI":"10.1002\/pbc.27236","article-title":"Comparison of Fixed versus Traditional Weight-Based Dosing of Rasburicase in a Pediatric Population","volume":"65","author":"Savva","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12288-018-0938-9","article-title":"Efficacy of Single Dose Rasburicase (1.5 Mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome","volume":"34","author":"Philips","year":"2018","journal-title":"Indian. J. Hematol. Blood Transfus."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"TLS Expert Panel Recommendations for the Evaluation of Risk and Prophylaxis of Tumour Lysis Syndrome (TLS) in Adults and Children with Malignant Diseases: An Expert TLS Panel Consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 Genotyping to Prevent Allopurinol Induced Severe Cutaneous Adverse Reactions in Taiwan: National Prospective Cohort Study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00467-006-0287-z","article-title":"Acute Renal Failure from Xanthine Nephropathy during Management of Acute Leukemia","volume":"22","author":"LaRosa","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1007\/s00467-024-06413-6","article-title":"Allopurinol Use Leading to Xanthine Nephrolithiasis in Pediatric Tumor Lysis Syndrome: A Case Series","volume":"39","author":"Goswami","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","article-title":"Recombinant Urate Oxidase (Rasburicase) in the Prevention and Treatment of Malignancy-Associated Hyperuricemia in Pediatric and Adult Patients: Results of a Compassionate-Use Trial","volume":"15","author":"Pui","year":"2001","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2010.01457.x","article-title":"A Single, Fixed Dose of Rasburicase (6 Mg Maximum) for Treatment of Tumor Lysis Syndrome in Adults","volume":"85","author":"Giraldez","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_42","first-page":"S84","article-title":"Single Dose\/Single Vial Rasburicase in the Management of Pediatric Patients with Hyperuricemia\/Tumor Lysis Syndrome","volume":"60","author":"Dwivedi","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_43","first-page":"S8","article-title":"A Single Dose of Rasburicase Is Sufficient for Treatment of Hyperuricemia in Children: Case Series with Review of Literature","volume":"60","author":"Martin","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1007\/s00277-023-05364-6","article-title":"Rasburicase-Induced Hemolytic Anemia and Methemoglobinemia: A Systematic Review of Current Reports","volume":"103","author":"Hammami","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/10781552221075239","article-title":"Rasburicase Induced Methemoglobinemia: A Systematic Review of Descriptive Studies","volume":"28","author":"Vidhyashree","year":"2022","journal-title":"J. Oncol. Pharm. Pr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjh.18464","article-title":"Rasburicase-Induced Methaemoglobinaemia and Catastrophic Oxidative Haemolysis in Undiagnosed G6PD Deficiency","volume":"200","author":"Wilson","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/71\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:12:04Z","timestamp":1766207524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["hematolrep17060071"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17060071","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}